Market closed
2seventy bio/$TSVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 2seventy bio
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Ticker
$TSVT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
65
ISIN
US9013841070
Website
2seventy bio Metrics
BasicAdvanced
$266M
-
-$0.08
1.05
-
Price and volume
Market cap
$266M
Beta
1.05
52-week high
$5.04
52-week low
$2.29
Average daily volume
1M
Financial strength
Current ratio
4.797
Quick ratio
4.694
Long term debt to equity
104.226
Total debt to equity
112.059
Management effectiveness
Return on assets (TTM)
-7.49%
Return on equity (TTM)
-1.94%
Valuation
Price to revenue (TTM)
5.413
Price to book
1.22
Price to tangible book (TTM)
1.26
Price to free cash flow (TTM)
-4.831
Growth
Revenue change (TTM)
-32.07%
Earnings per share change (TTM)
-98.19%
3-year revenue growth (CAGR)
-1.78%
3-year earnings per share growth (CAGR)
-81.27%
What the Analysts think about 2seventy bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 2seventy bio stock.
2seventy bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
2seventy bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
2seventy bio News
AllArticlesVideos
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Business Wire·3 weeks ago
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Business Wire·2 months ago
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 2seventy bio stock?
2seventy bio (TSVT) has a market cap of $266M as of May 10, 2025.
What is the P/E ratio for 2seventy bio stock?
The price to earnings (P/E) ratio for 2seventy bio (TSVT) stock is 0 as of May 10, 2025.
Does 2seventy bio stock pay dividends?
No, 2seventy bio (TSVT) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next 2seventy bio dividend payment date?
2seventy bio (TSVT) stock does not pay dividends to its shareholders.
What is the beta indicator for 2seventy bio?
2seventy bio (TSVT) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.